OncoMatch/Clinical Trials/NCT04043494
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Is NCT04043494 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for lymphoblastic lymphoma, childhood.
Treatment: Cyclophosphamide · Cytarabine · Dexamethasone · Daunorubicin · Doxorubicin · Ifosfamide · 6-Mercaptopurine · Methotrexate · PEG asparaginase · Prednisone · Prednisolone · Thioguanine · Vincristine · Vindesine — Primary objectives: * Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) * Randomization R2, only patients with high risk LBL eligible: to examine, whether the probability of event-free survival (pEFS) in these patients can be improved by receiving an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Demographics
Prior therapy
Cannot have received: steroid
Exception: pre-treatment with ≥ 1 mg/kg/d for more than two weeks during the last month before diagnosis
steroid pre-treatment with ≥ 1 mg/kg/d for more than two weeks during the last month before diagnosis
Cannot have received: cytostatic drugs
pre-treatment with cytostatic drugs
Lab requirements
Kidney function
severe renal impairment (creatinine clearance less than 20 ml/min) [excluded]
Liver function
severe hepatic impairment (bilirubin >3 times ULN, transaminases >10 times ULN) [excluded]
Cardiac function
myocardial insufficiency, severe arrhythmias [excluded]
severe renal impairment (creatinine clearance less than 20 ml/min); severe hepatic impairment (bilirubin >3 times ULN, transaminases >10 times ULN); myocardial insufficiency, severe arrhythmias
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04043494 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 18 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify